CK Life Sciences International (Holdings), Inc. (0775) AI Stock Analysis

• Market Cap: HK$8.46B
• Dividend Yield: N/A
• Average Volume (3M): 7.56M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.83
• Revenue Growth: 2.10%
• EPS Growth: -1350.00%
• Country: HK
• Employees: 2,033
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 9,611,072,000
• 10 Day Avg. Volume: 13,068,694
• 30 Day Avg. Volume: 7,559,299
• PEG Ratio: 0.04
• Price to Book (P/B): 1.12
• Price to Sales (P/S): 0.71
• P/FCF Ratio: 25.58
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 52 Neutral
• Price Target: HK$1.00 ▲(11.11% Upside)

The overall stock score is primarily influenced by financial performance challenges, including negative net income and high leverage. Technical analysis indicates a bearish trend with potential for reversal, while valuation metrics highlight unprofitability. The absence of earnings call data and corporate events limits additional insights.

CK Life Sciences International (Holdings), Inc. Business Overview & Revenue Model

Company Description

CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, researches, develops, manufactures, commercializes, markets, and sells health and agriculture-related products in the Asia Pacific and North America. It manufactures and markets plant protection products and soluble fertilizers; manufactures, blends, distributes, and sells fertilizers, pesticides, and related agricultural products; manufactures and distributes horticultural products for the home gardening market; and produces non-sterile prescription and over-the-counter medicines. The company is also involved in the contract manufacturing of complementary healthcare medicines, pharmaceutical products, and cosmetics; licensing of registration activities and the importation of finished agricultural goods; holding of land and buildings; financing activities; investment in financial instruments and vineyards; trading of biotechnology products and nutritional supplements; and manufacturing, wholesaling, retailing, and distribution of nutraceutical products. In addition, it distributes turf management machinery, hardware, equipment, and accessories, as well as turf fertilizers, chemicals, and professional pest products; produces, refines, and distributes salt products; and provides research and development services for biotechnology and life sciences technology products. Further, it researches, develops, manufactures, and commercializes drug products to treat pain and melanoma; supplies raw materials for nutritional health, pharmaceutical, cosmetics, personal care, and food segments; and offers packing and asset management services. CK Life Sciences Int'l., (Holdings) Inc. was founded in 1999 and is headquartered in Tai Po, Hong Kong.

How the Company Makes Money

CK Life Sciences makes money through a diversified revenue model that includes the sale of pharmaceuticals, nutraceuticals, and other health-related products. The company generates revenue from the development and commercialization of proprietary and licensed pharmaceutical products targeting various therapeutic areas. Additionally, its nutraceuticals business, which includes dietary supplements and health products, contributes significantly to its revenue. CK Life Sciences also earns income from its agriculture-related businesses, involving the development and sale of environmentally friendly fertilizers and crop protection products. Strategic partnerships and collaborations with other companies in the biotechnology and healthcare sectors further enhance its revenue streams.

CK Life Sciences International (Holdings), Inc. Financial Statement Overview

Summary

CK Life Sciences is facing profitability challenges with a negative net income in 2024 despite stable revenue growth. Operational efficiency has improved, but high leverage and a declining equity ratio raise financial stability concerns. Positive operating and free cash flows suggest some operational strength, yet the cash flow decline indicates potential cash management issues.

Income Statement

The company has shown a modest revenue growth of 3.75% from 2023 to 2024. However, it reported a negative net income in 2024, resulting in a net profit margin of -2.29%, indicating profitability challenges. The gross profit margin remained stable at 30.64%, and the EBIT margin improved to 14.18%, suggesting operational efficiency improvements despite bottom-line issues.

Balance Sheet

The debt-to-equity ratio increased to 1.74, indicating a higher leverage, which could pose financial risks. The equity ratio decreased to 32.53%, reflecting a lower proportion of equity financing in the asset structure. ROE turned negative due to the net loss, highlighting the strain on shareholder returns.

Cash Flow

Operating cash flow remained positive, although it decreased by 31.23% from the previous year. Free cash flow declined by 30.74%, suggesting reduced excess cash for reinvestment. The free cash flow to net income ratio is not meaningful due to the negative net income, but the company maintained a positive free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.49B	5.52B	5.32B	5.28B	5.40B	4.94B
Gross Profit	1.69B	1.69B	1.64B	1.63B	1.63B	1.41B
EBITDA	9.39M	337.27M	624.75M	469.51M	449.14M	353.62M
Net Income	-278.39M	-126.55M	17.25M	131.96M	162.80M	125.23M
Balance Sheet
Total Assets	11.29B	10.79B	11.25B	11.27B	11.73B	11.98B
Cash, Cash Equivalents and Short-Term Investments	797.84M	571.21M	676.16M	704.13M	902.47M	971.71M
Total Debt	6.50B	6.10B	5.93B	5.95B	6.21B	6.19B
Total Liabilities	7.63B	7.28B	7.06B	7.11B	7.23B	7.26B
Stockholders Equity	3.65B	3.51B	4.19B	4.16B	4.50B	4.72B
Cash Flow
Free Cash Flow	5.54M	157.00M	222.35M	146.69M	206.33M	151.12M
Operating Cash Flow	202.07M	353.53M	514.18M	363.66M	423.57M	530.96M
Investing Cash Flow	17.52M	-96.64M	-67.96M	-22.12M	-257.88M	-457.31M
Financing Cash Flow	20.56M	-341.98M	-477.95M	-515.34M	-220.08M	168.74M

CK Life Sciences International (Holdings), Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0775, the sentiment is Positive. The current price of 0.9 is below the 20-day moving average (MA) of 0.93, below the 50-day MA of 0.93, and above the 200-day MA of 0.78, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 45.52 is Neutral, neither overbought nor oversold. The STOCH value of 35.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0775.

CK Life Sciences International (Holdings), Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2315	―	HK$11.11B	77.71	16.13%	―	48.38%	―
0775	―	HK$8.46B	-30.34	-7.26%	―	2.10%	-1350.00%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2142	―	HK$11.43B	17.53	35.80%	―	59.70%	239.97%
1672	―	HK$9.11B	-32.00	-12.74%	―	-76.58%	-4.90%
1477	―	HK$6.87B	-23.42	-7.71%	―	74.73%	32.13%

CK Life Sciences International (Holdings), Inc. Corporate Events

CK Life Sciences Announces Strategic Transaction to Enhance Cancer Treatment Pipeline

CK Life Sciences International (Holdings), Inc. announced a transaction involving the sale of 100% membership interests in a subsidiary to a purchaser for US$125 million, with additional milestone payments up to US$95 million. The transaction aims to combine the businesses of Polynoma and the purchaser, enhancing their therapeutic pipeline with complementary cancer treatments and leveraging the purchaser’s Nasdaq listing to promote and fundraise for the development of seviprotimut-L, a melanoma vaccine.

The most recent analyst rating on (HK:0775) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on CK Life Sciences International (Holdings), Inc. stock, see the HK:0775 Stock Forecast page.

CK Life Sciences Announces Waiver Agreement in Sale Transaction

CK Life Sciences International (Holdings), Inc. announced a waiver agreement regarding the sale of a target company to a purchaser. This waiver involves the Cash Settlement Right and Repurchase Right related to Purchaser Preferred Stock Payment Shares. The transaction is considered a material variation to the Sale Agreement, and the company has confirmed that the terms are fair and reasonable, aligning with the interests of the company and its shareholders.

The most recent analyst rating on (HK:0775) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on CK Life Sciences International (Holdings), Inc. stock, see the HK:0775 Stock Forecast page.

CK Life Sciences Boosts R&D Investments, Reports Interim Loss

CK Life Sciences reported a loss of HK$150.8 million for the first half of 2025, attributed to a strategic increase in R&D investments to HK$235.3 million, aimed at accelerating its research programs. This investment marks significant progress in their pharmaceuticals R&D, including advancements in cancer vaccines and diagnostics, with potential implications for improved cancer treatment and early detection, positioning the company as a key player in addressing unmet needs in the oncology sector.